Australian biotech market watch 19/03/10
Friday, 19 March, 2010
At the end of a buoyant week for the stock market, the All Ordinaries is flat as of midday today, up a marginal 6.5 points to 4,884.20.
After Cochlear (ASX:COH) announced a change of chairman as Tommie Bergman indicated he was to step down, stocks in the company have seen a bump, up 3.86% since the announcement to $69.30 today.
Two of the other Big Three have remained fairly steady, with CSL (ASX:CSL) hovering around the $36 mark and ResMed loitering around $6.73.
Xenotransplantation specialists, Living Cell Technology (ASX:LCT), saw a steep rise early in the week, but much of the gains have been lost Thursday and today, with it dropping 2c to 21c, although that's still above the sub-20c mark it was trading at last week.
Mesoblast (ASX:MSB) is fairly steady today, up 1c to $2.06, but saw a tidy 5% lift in yesterday's trading.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
